文献速递泌尿男性生殖肿瘤

接受一线和二线阿比特龙及恩扎卢胺治疗的转移性去势抵抗性前列腺癌男性患者循环肿瘤细胞中雄激素受体剪接变异体-7 mRNA检测的临床意义

Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide.
PubMed 文献 · J Clin Oncol · 2017-04-06

研究前瞻性纳入202例开始阿比特龙或恩扎卢胺治疗的去势抵抗性前列腺癌患者,采用基于循环肿瘤细胞的雄激素受体剪接变异体-7 mRNA检测法评估预后价值。结果显示,循环肿瘤细胞阴性患者结局最佳,循环肿瘤细胞阳性/雄激素受体剪接变异体-7阴性患者居中,循环肿瘤细胞阳性/雄激素受体剪接变异体-7阳性患者最差,且在多变量模型中仍显著。作者认为该检测应采用三分类预后 category 解读。

要点

  • 循环肿瘤细胞阳性/雄激素受体剪接变异体-7阳性患者更易有Gleason评分≥8、诊断时转移、更高PSA、既往阿比特龙或恩扎卢胺及紫杉烷使用。
  • 总队列及一线和二线新型内分泌治疗亚组中,结局由好到差依次为循环肿瘤细胞阴性、循环肿瘤细胞阳性/雄激素受体剪接变异体-7阴性、循环肿瘤细胞阳性/雄激素受体剪接变异体-7阳性。
  • 作者认为该检测应采用循环肿瘤细胞阴性、循环肿瘤细胞阳性/雄激素受体剪接变异体-7阴性、循环肿瘤细胞阳性/雄激素受体剪接变异体-7阳性三分类预后 category 解读。

核心结论

  • 该扩展分析进一步表征了基于循环肿瘤细胞的雄激素受体剪接变异体-7 mRNA检测在预测接受一线和二线新型内分泌治疗的去势抵抗性前列腺癌患者结局中的重要性。
  • 据作者所知,这是首个提示该检测应采用循环肿瘤细胞阴性、循环肿瘤细胞阳性/雄激素受体剪接变异体-7阴性、循环肿瘤细胞阳性/雄激素受体剪接变异体-7阳性三个独立预后 category 解读的研究。

研究设计与样本

  • 前瞻性纳入202例开始阿比特龙或恩扎卢胺治疗的去势抵抗性前列腺癌患者。
  • 采用基于循环肿瘤细胞的雄激素受体剪接变异体-7 mRNA检测法,评估循环肿瘤细胞检出(阳性 vs 阴性)和雄激素受体剪接变异体-7检出(阳性 vs 阴性)的预后价值。
  • 分析≥50%前列腺特异性抗原反应、前列腺特异性抗原进展无生存期、临床和影像学进展无生存期及总生存期。
  • 构建多变量模型,校正前列腺特异性抗原、Gleason总和、既往激素治疗次数、既往阿比特龙或恩扎卢胺使用、既往紫杉烷使用、内脏转移 presence 及东部肿瘤协作组评分。
  • 分别分析一线和二线新型内分泌治疗 setting。

主要发现

  • 循环肿瘤细胞阴性、循环肿瘤细胞阳性/雄激素受体剪接变异体-7阴性、循环肿瘤细胞阳性/雄激素受体剪接变异体-7阳性患者的中位随访时间分别为15.0、21.7和14.6个月。
  • 循环肿瘤细胞阳性/雄激素受体剪接变异体-7阳性患者更可能有Gleason评分≥8(P = .05)、诊断时转移性疾病(P = .01)、更高前列腺特异性抗原(P < .01)、既往阿比特龙或恩扎卢胺使用(P = .03)、既往紫杉烷使用(P = .02)及东部肿瘤协作组评分≥1(P = .01)。
  • 总队列及分别一线和二线新型内分泌治疗队列中,结局均为循环肿瘤细胞阴性患者最佳、循环肿瘤细胞阳性/雄激素受体剪接变异体-7阴性患者居中、循环肿瘤细胞阳性/雄激素受体剪接变异体-7阳性患者最差。
  • 这些相关性在多变量模型中仍显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose We reported previously that the detection of androgen receptor splice variant-7 (AR-V7) mRNA in circulating tumor cells (CTCs) correlated with poor outcomes from the use of abiraterone and enzalutamide in patients with castration-resistant prostate cancer (CRPC). Here, we expanded our cohort size to better characterize the prognostic significance of AR-V7 in this setting. Methods We prospectively enrolled 202 patients with CRPC starting abiraterone or enzalutamide and investigated the prognostic value of CTC detection (+ v -) and AR-V7 detection (+ v -) using a CTC-based AR-V7 mRNA assay. We examined ≥ 50% prostate-specific antigen (PSA) responses, PSA progression-free survival, clinical and radiologic progression-free survival, and overall survival. We constructed multivariable models adjusting for PSA, Gleason sum, number of prior hormone therapies, prior abiraterone or enzalutamide use, prior taxane use, presence of visceral metastases, and Eastern Cooperative Oncology Group score. We also separately examined the first-line and second-line novel hormonal therapy (NHT) settings. Results Median follow-up times were 15.0, 21.7, and 14.6 months for CTC-, CTC+/AR-V7- and CTC+/AR-V7+ patients, respectively. CTC+/AR-V7+ patients were more likely to have Gleason scores ≥ 8 ( P = .05), metastatic disease at diagnosis ( P = .01), higher PSA ( P < .01), prior abiraterone or enzalutamide use ( P = .03), prior taxane use ( P = .02), and Eastern Cooperative Oncology Group ≥ 1 ( P = .01). Outcomes for the overall cohort (and separately for the first-line and second-line NHT cohorts) were best for CTC- patients, intermediate for CTC+/AR-V7- patients, and worse for CTC+/AR-V7+ patients. These correlations remained significant in multivariable models. Conclusion This expanded analysis further characterizes the importance of CTC-based AR-V7 mRNA detection in predicting outcomes in patients with CRPC receiving first- and second-line NHT and, to the best of our knowledge, is the first to suggest that this assay be interpreted using three separate prognostic categories: CTC-, CTC+/AR-V7-, and CTC+/AR-V7+.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Antonarakis ES, Lu C, Luber B, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. J Clin Oncol. 2017. PMID: 28384066. doi:10.1200/JCO.2016.70.1961

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。